vs
Amphastar Pharmaceuticals, Inc.（AMPH）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是Amphastar Pharmaceuticals, Inc.的1.1倍（$200.5M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 2.2%，领先11.1%），ROGERS CORP同比增速更快（5.2% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $1.1M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -3.3%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
AMPH vs ROG — 直观对比
营收规模更大
ROG
是对方的1.1倍
$183.1M
营收增速更快
ROG
高出7.1%
-1.8%
净利率更高
AMPH
高出11.1%
2.2%
自由现金流更多
AMPH
多$23.5M
$1.1M
两年增速更快
AMPH
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $200.5M |
| 净利润 | $24.4M | $4.5M |
| 毛利率 | 46.8% | 32.2% |
| 营业利润率 | 19.4% | — |
| 净利率 | 13.3% | 2.2% |
| 营收同比 | -1.8% | 5.2% |
| 净利润同比 | -35.7% | 421.4% |
| 每股收益（稀释后） | $0.51 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $183.1M | $201.5M | ||
| Q3 25 | $191.8M | $216.0M | ||
| Q2 25 | $174.4M | $202.8M | ||
| Q1 25 | $170.5M | $190.5M | ||
| Q4 24 | $186.5M | $192.2M | ||
| Q3 24 | $191.2M | $210.3M | ||
| Q2 24 | $182.4M | $214.2M |
净利润AMPHROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $24.4M | $4.6M | ||
| Q3 25 | $17.4M | $8.6M | ||
| Q2 25 | $31.0M | $-73.6M | ||
| Q1 25 | $25.3M | $-1.4M | ||
| Q4 24 | $38.0M | $-500.0K | ||
| Q3 24 | $40.4M | $10.7M | ||
| Q2 24 | $37.9M | $8.1M |
毛利率AMPHROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 46.8% | 31.5% | ||
| Q3 25 | 51.4% | 33.5% | ||
| Q2 25 | 49.6% | 31.6% | ||
| Q1 25 | 50.0% | 29.9% | ||
| Q4 24 | 46.5% | 32.1% | ||
| Q3 24 | 53.3% | 35.2% | ||
| Q2 24 | 52.2% | 34.1% |
营业利润率AMPHROG
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 3.5% | ||
| Q3 25 | 13.2% | 7.3% | ||
| Q2 25 | 24.2% | -33.3% | ||
| Q1 25 | 21.9% | -0.2% | ||
| Q4 24 | 24.2% | -6.6% | ||
| Q3 24 | 29.8% | 6.9% | ||
| Q2 24 | 30.3% | 5.3% |
净利率AMPHROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 13.3% | 2.3% | ||
| Q3 25 | 9.0% | 4.0% | ||
| Q2 25 | 17.8% | -36.3% | ||
| Q1 25 | 14.8% | -0.7% | ||
| Q4 24 | 20.4% | -0.3% | ||
| Q3 24 | 21.1% | 5.1% | ||
| Q2 24 | 20.8% | 3.8% |
每股收益（稀释后）AMPHROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.51 | $0.20 | ||
| Q3 25 | $0.37 | $0.48 | ||
| Q2 25 | $0.64 | $-4.00 | ||
| Q1 25 | $0.51 | $-0.08 | ||
| Q4 24 | $0.74 | $-0.04 | ||
| Q3 24 | $0.78 | $0.58 | ||
| Q2 24 | $0.73 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $195.8M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $1.2B |
| 总资产 | $1.6B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $282.8M | $197.0M | ||
| Q3 25 | $276.2M | $167.8M | ||
| Q2 25 | $231.8M | $157.2M | ||
| Q1 25 | $236.9M | $175.6M | ||
| Q4 24 | $221.6M | $159.8M | ||
| Q3 24 | $250.5M | $146.4M | ||
| Q2 24 | $217.8M | $119.9M |
总债务AMPHROG
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
股东权益AMPHROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $788.8M | $1.2B | ||
| Q3 25 | $776.7M | $1.2B | ||
| Q2 25 | $757.5M | $1.2B | ||
| Q1 25 | $751.3M | $1.3B | ||
| Q4 24 | $732.3M | $1.3B | ||
| Q3 24 | $727.7M | $1.3B | ||
| Q2 24 | $713.3M | $1.3B |
总资产AMPHROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B |
负债/权益比AMPHROG
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $1.1M |
| 自由现金流率自由现金流/营收 | 13.4% | 0.5% |
| 资本支出强度资本支出/营收 | 4.5% | 2.3% |
| 现金转化率经营现金流/净利润 | 1.35× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $70.1M |
8季度趋势，按日历期对齐
经营现金流AMPHROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $32.9M | $46.9M | ||
| Q3 25 | $52.6M | $28.9M | ||
| Q2 25 | $35.6M | $13.7M | ||
| Q1 25 | $35.1M | $11.7M | ||
| Q4 24 | $29.0M | $33.7M | ||
| Q3 24 | $60.0M | $42.4M | ||
| Q2 24 | $69.1M | $22.9M |
自由现金流AMPHROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $24.6M | $42.2M | ||
| Q3 25 | $47.2M | $21.2M | ||
| Q2 25 | $25.0M | $5.6M | ||
| Q1 25 | $24.4M | $2.1M | ||
| Q4 24 | $16.6M | $18.3M | ||
| Q3 24 | $46.2M | $25.2M | ||
| Q2 24 | $63.1M | $8.8M |
自由现金流率AMPHROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 13.4% | 20.9% | ||
| Q3 25 | 24.6% | 9.8% | ||
| Q2 25 | 14.3% | 2.8% | ||
| Q1 25 | 14.3% | 1.1% | ||
| Q4 24 | 8.9% | 9.5% | ||
| Q3 24 | 24.1% | 12.0% | ||
| Q2 24 | 34.6% | 4.1% |
资本支出强度AMPHROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 4.5% | 2.3% | ||
| Q3 25 | 2.8% | 3.6% | ||
| Q2 25 | 6.1% | 4.0% | ||
| Q1 25 | 6.3% | 5.0% | ||
| Q4 24 | 6.7% | 8.0% | ||
| Q3 24 | 7.2% | 8.2% | ||
| Q2 24 | 3.3% | 6.6% |
现金转化率AMPHROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 1.35× | 10.20× | ||
| Q3 25 | 3.03× | 3.36× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 3.96× | ||
| Q2 24 | 1.82× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ROG
暂无分部数据
